Semaglutide for Men: How It Works, Doses, and What to Expect

What semaglutide is and what it treats

Semaglutide is a GLP-1 receptor agonist, an engineered version of the gut hormone GLP-1 that resists the enzyme that would normally break it down within minutes. Because it lasts, one injection covers a full week. It is FDA-approved in two branded forms with two different indications. Ozempic is approved for adults with type 2 diabetes to improve blood sugar control and, in adults with type 2 diabetes and established cardiovascular disease, to reduce the risk of major cardiovascular events. Wegovy is approved at a higher dose for chronic weight management, and its label now also includes reducing cardiovascular event risk in certain adults with cardiovascular disease and overweight or obesity.

Same molecule, different doses, different approved uses. That distinction matters for insurance, for eligibility, and for what a provider can legitimately prescribe it for.

What the semaglutide trials actually showed

The evidence base here is unusually strong. In STEP 1, adults with obesity taking semaglutide 2.4 mg weekly lost about 15 percent of body weight over 68 weeks against roughly 2.4 percent on placebo. STEP 4 tested what happens on discontinuation: people who stopped regained about two-thirds of the lost weight within a year, while those who continued kept losing. SELECT, published in 2023, showed that in adults with established cardiovascular disease and overweight or obesity but without diabetes, semaglutide reduced major cardiovascular events by about 20 percent. That last trial is why the conversation shifted from cosmetic to cardiometabolic.

How semaglutide compares within the class

Compared with tirzepatide, semaglutide is a single GLP-1 agonist rather than a dual GIP/GLP-1 agent, and average weight loss in the tirzepatide trials was larger. Compared with liraglutide, semaglutide is dosed weekly instead of daily and produced greater weight loss in head-to-head diabetes trials. Compared with oral semaglutide (Rybelsus), the injection is the same molecule delivered more reliably, without the strict fasting-and-water routine the tablet requires. None of that makes semaglutide the automatic choice; it makes it a well-characterized one.

The boxed warning and who should not take it

Semaglutide carries an FDA boxed warning based on rodent studies showing thyroid C-cell tumors, including medullary thyroid carcinoma. It is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Whether the rodent finding translates to humans is not established, but the contraindication is firm. Beyond that, pancreatitis has been reported: if you develop severe, persistent abdominal pain, stop and seek care, because acute pancreatitis is a recognized risk. Gallbladder problems, including gallstones, occur more often during rapid weight loss. A history of these conditions changes eligibility, which is why a licensed provider reviews your full history.

Side effects men actually report

The common side effects are gastrointestinal: nausea, diarrhea, constipation, vomiting, reflux, and burping. They cluster around dose increases and usually ease within days to a couple of weeks. Serious reactions are less common but real and include pancreatitis, gallbladder disease, kidney problems from dehydration if vomiting is severe, and worsening of diabetic eye disease in people with diabetes. Because semaglutide slows stomach emptying, tell any provider about it before surgery or a procedure involving sedation.

The lean-mass issue after 40

Weight lost on semaglutide is not all fat. A portion is lean mass, and for a man already losing muscle to age that is the tissue you least want to give up. The practical response is consistent: eat enough protein and train against resistance while you lose. If weight-related low testosterone is part of your picture, losing visceral fat can help, but that is a separate evaluation covered under testosterone therapy. Obesity is also a common driver of erectile dysfunction, which is why weight loss and sexual health often improve together.

The compounded semaglutide question

Compounded semaglutide flooded the market during branded shortages. It is not an FDA-approved product, is not reviewed for potency or purity, and the FDA has flagged dosing errors and adulterated products. As branded supply recovered, the legal room for mass compounding shrank. Cheap injectable semaglutide from an unclear source is a reason to ask hard questions, not a bargain.

Prescription-only, and how eligibility is decided

Semaglutide is prescription-only. A licensed provider determines eligibility based on your BMI, weight-related conditions, medical history, and current medications. The standard weight-management thresholds are a BMI of 30 or higher, or 27 or higher with a qualifying condition. OmenRx does not prescribe or dispense; we explain the medication and refer to licensed care partners.